AI assistant
PERRIGO Co plc — Director's Dealing 2016
Feb 18, 2016
31387_dirs_2016-02-18_36a13315-74f9-4102-acbb-12e83bc6c3de.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3/A — Form 3/A
Issuer: PROTEOSTASIS THERAPEUTICS, INC. (PTI)
CIK: 0001445283
Period of Report: 2016-02-10
Reporting Person: PERRIGO SCIENCE ONE LTD. (10% Owner)
Reporting Person: PERRIGO CORP LTD. (10% Owner)
Reporting Person: ELAN PHARMA INTERNATIONAL LTD. (10% Owner)
Reporting Person: PERRIGO HOLDINGS LTD. (10% Owner)
Reporting Person: PERRIGO Co plc (10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Convertible Redeemable Preferred Stock | $ | Common Stock (2416612) | Direct | ||
| Series B Convertible Redeemable Preferred Stock | $ | Common Stock (366455) | Direct |
Footnotes
F1: The Series A Convertible Redeemable Preferred Stock (the "Series A Shares") are convertible on a 10.8102-to-1 basis into the Issuer's Common Stock at any time at the election of the Reporting Person and will automatically convert, together with the accrued but unpaid dividends, upon closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3. The Series A Shares do not have an expiration date.
F2: Perrigo Science One Ltd. ("Science") (formerly Elan Science One Ltd.) is the direct owner of these securities. Science is a direct or indirect, wholly-owned subsidiary of each of the other reporting persons.
F3: The Series B Convertible Redeemable Preferred Stock (the "Series B Shares") are convertible on a 10.8102-to-1 basis into the number of shares of the Issuer's Common Stock as shown in column 3 at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering. The Series B Shares do not have an expiration date.